Vanguard Capital Management
PASG icon

Vanguard Capital Management’s Passage Bio PASG Stock Holding History

Vanguard Capital Management’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$556K Hold
113,964
– – ﹤0.01% 3702
2026
Q1 		$895K Buy
+113,964
New +$1.18M ﹤0.01% 3574

Other funds holding PASG

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management's PASG Position: Q2 2026 in Review

Vanguard Capital Management held its Passage Bio (PASG) position steady in Q2 2026 at 113,964 shares worth $556K. The position accounts for ﹤0.01% of the portfolio, ranked #3702.

Vanguard Capital Management first reported a position in PASG in Q1 2026 and has held it in 2 quarters since. The position peaked at $895K in Q1 2026. 28 funds tracked by Wall St. Rank hold PASG as of Q2 2026.

  • Vanguard Capital Management held 113,964 shares of Passage Bio worth $556K as of Q2 2026.
  • Vanguard Capital Management left its Passage Bio share count unchanged in Q2 2026.
  • Passage Bio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3702 holding.
  • Vanguard Capital Management first reported a position in Passage Bio in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Passage Bio position peaked at $895K in Q1 2026.
  • 28 funds tracked by Wall St. Rank held Passage Bio as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.